ACTRN12620000191998已完成1 期
A single dose, blinded, balanced, randomised, two-treatment, four period, two sequence, four-way fully replicated crossover bioequivalence study comparing 3 x 200 mcg (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid tablets with 3 x 200 mcg (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid tablets in healthy male and female subjects under fasting conditions.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy males and females
- •Aged between 18 and 55
- •Non-smoker
- •BMI between 18.5 and 32 inclusive
- •Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- •Able to provide written informed consent
排除标准
- •Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches, hypothyroidism, hyperthyroidism and/or cardiovascular disorders.
- •Concomitant drug therapy of any kind
- •Sensitivity to any of the medicines or ingredients
- •History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •Smoker (anyone who has smoked in the last 6 months)
- •History of alcohol or drug abuse or dependency
- •Participation in a drug study within 60 days of the start of the study or donated blood in the 30 days preceding the study.
- •Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
研究者
相似试验
撤回
1 期
Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fasting condition in healthy male and female volunteers.Dimethyl (2E)-but-2-enedioate is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.Neurological - Multiple sclerosisACTRN12621000775819Zenith Technology Corporation Limited39
撤回
1 期
Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fed conditions in healthy male and female volunteers.Dimethyl (2E)-but-2-enedioate is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.Neurological - Multiple sclerosisACTRN12621000887875Zenith Technology Corporation Limited39
已完成
1 期
Comparative assessment of the absorption of a generic formulation of paracetamol / ibuprofen / doxylamine tablet against the innovator paracetamol / codeine phosphate hemihydrate / doxylamine succinate tablets and paracetamol / ibuprofen tablet conducted under fasting conditions in healthy male and female volunteersPainFeverInflammationInflammatory and Immune System - Other inflammatory or immune system disordersAnaesthesiology - Pain managementAllergyACTRN12619001017112Zenith Technology Corporation Limited24
撤回
1 期
Comparative assessment of the absorption of a generic formulation of 4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol hydrogen tartrate oral liquid against the innovator 4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol hydrogen tartrate oral liquid conducted under fasting conditions in healthy male and female volunteers.4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol hydrogen tartrate oral liquid is used to provide temporary relief for persistent unproductive and dry coughsAnaesthesiology - Pain managementInflammatory and Immune System - Other inflammatory or immune system disordersRespiratory - Other respiratory disorders / diseasesACTRN12621001252808Zenith Technology Corporation Limited30
已完成
1 期
Comparative assessment of the absorption of a generic formulation of bexarotene capsule against the innovator bexarotene capsule conducted under fed conditions in healthy male volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of bexarotene with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, bexarotene is a member of a subclass of retinoids. Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL).Bioequivalence study conducted in healthy volunteers comparing two formulations of bexarotene with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, bexarotene is a member of a subclass of retinoids. Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL).Cancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaACTRN12616000374460Zenith Technology Corp Ltd58